Atricure Inc (ATRC)

$41.77 +0.33 (0.80%)
Market Cap 1.95B
Revenue (ttm) 465.31M
Net Income (ttm) -44.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.61%
Debt to Equity Ratio 0.13
Volume 340,200
Avg Vol 551,936
Day's Range N/A - N/A
Shares Out 49.72M
Stochastic %K 91%
Beta 1.40
Analysts Strong Sell
Price Target $52.33

Company Profile

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias;...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 513 755 4100
Fax: 513 755 4567
Address:
7555 Innovation Way, Mason, United States
JarvisFlow
JarvisFlow Dec. 16 at 3:36 PM
JP Morgan updates rating for AtriCure ( $ATRC ) to Overweight, target set at 42 → 48.
0 · Reply
10xStacks
10xStacks Dec. 12 at 5:46 PM
$ATRC go
1 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 4:21 PM
$ATRC unveils breakthrough dual-energy platform in surgical ablation! 🚀 📈 First patients successfully treated, advancing ATRC's platform toward a planned clinical trial next year. 🩺 Year-to-date shares up 35.5%, outshining industry’s 1.1% growth. 🔍 Zacks Rank #2 (Buy) signals bullish momentum. See what this means for ATRC's future growth 👉 https://www.zacks.com/stock/news/2803792/atrc-treats-first-patients-using-novel-dual-energy-pfa-rfa-platform?cid=sm-stocktwits-2-2803792-body-24653&ADID=SYND_STOCKTWITS_TWEET_2_2803792_BODY_24653
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 3:21 PM
Big milestone alert for $ATRC 🚀 ATRC just treated its first patients with its dual-energy PFA-RFA platform — a meaningful step as it moves toward a clinical trial next year. That’s the kind of early traction investors watch closely. Full details here 👉 https://www.zacks.com/stock/news/2803792/atrc-treats-first-patients-using-novel-dual-energy-pfa-rfa-platform?cid=sm-stocktwits-2-2803792-teaser-24638&ADID=SYND_STOCKTWITS_TWEET_2_2803792_TEASER_24638
0 · Reply
Arcides
Arcides Nov. 30 at 5:35 PM
$ATRC chart is a mess, too much volatility, was this a shakeout?
0 · Reply
RunnerSignals
RunnerSignals Nov. 20 at 8:46 PM
mini-pulse pop! $AMZN $APTV $AR $ATRC $CYBR all waking up some bouncing some breaking and some just teasing. charts heating up… https://stocksrunner.com/news/2025-11-20-daily-market-pulse-advanced-technical-analysis
0 · Reply
maq34
maq34 Nov. 7 at 3:56 PM
$ATRC Raised 2025 Financial Outlook: Building on the strong results, AtriCure raised its full-year 2025 revenue projection to a range of $532 million to $534 million, and its adjusted EBITDA forecast to between $55 million and $57 million. PT of $54 and up…! $AMGN $ABBV $VRTX $GILD
0 · Reply
maq34
maq34 Nov. 7 at 3:53 PM
$ATRC $GILD $AMGN $ABBV $VRTX
0 · Reply
maq34
maq34 Nov. 7 at 3:43 PM
$ATRC Attractive price with solid product offering $ABBV $ASTRAZEN.NSE
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 8:27 PM
$ATRC Share Price: $31.75 Contract Selected: Apr 17, 2026 $30 Calls Buy Zone: $3.31 – $4.09 Target Zone: $6.32 – $7.72 Potential Upside: 80% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Latest News on ATRC
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference

Dec 17, 2025, 8:00 AM EST - 21 days ago

AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference

AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

Dec 11, 2025, 8:00 AM EST - 27 days ago

AtriCure Announces the First Patients Treated with Novel Dual Energy Platform

AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 7 weeks ago

AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference

AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 4:41 PM EST - 2 months ago

AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript

AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 11:16 PM EDT - 2 months ago

AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript

AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

Oct 29, 2025, 4:01 PM EDT - 2 months ago

AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025

AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial

Oct 28, 2025, 8:00 AM EDT - 2 months ago

AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial

AtriCure to Participate in Upcoming Investor Conferences

Oct 27, 2025, 8:00 AM EDT - 2 months ago

AtriCure to Participate in Upcoming Investor Conferences

AtriCure to Announce Third Quarter 2025 Financial Results

Oct 8, 2025, 8:00 AM EDT - 3 months ago

AtriCure to Announce Third Quarter 2025 Financial Results

AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation

Sep 9, 2025, 8:00 AM EDT - 4 months ago

AtriCure Announces the Launch of the cryoXT™ Device for Post-Operative Pain Management Following Amputation

AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 20, 2025, 8:00 AM EDT - 5 months ago

AtriCure to Participate in the 2025 Wells Fargo Healthcare Conference

AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 7:14 PM EDT - 5 months ago

AtriCure, Inc. (ATRC) Q2 2025 Earnings Call Transcript

AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025

Jul 29, 2025, 4:01 PM EDT - 5 months ago

AtriCure Reports Second Quarter 2025 Financial Results; Raises Financial Outlook for 2025

AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jul 28, 2025, 8:00 AM EDT - 5 months ago

AtriCure to Participate in the Canaccord Genuity 45th Annual Growth Conference

AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention

Jul 15, 2025, 8:00 AM EDT - 6 months ago

AtriCure Completes Enrollment in LeAAPS Clinical Trial for Stroke Prevention

AtriCure to Announce Second Quarter 2025 Financial Results

Jul 8, 2025, 8:00 AM EDT - 6 months ago

AtriCure to Announce Second Quarter 2025 Financial Results

AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 23, 2025, 8:00 AM EDT - 8 months ago

AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 9:34 PM EDT - 9 months ago

AtriCure, Inc. (ATRC) Q1 2025 Earnings Call Transcript

AtriCure Reports First Quarter 2025 Financial Results

Apr 29, 2025, 4:01 PM EDT - 9 months ago

AtriCure Reports First Quarter 2025 Financial Results

AtriCure Announces First Use of the AtriClip PRO-Mini® Device

Apr 10, 2025, 8:00 AM EDT - 9 months ago

AtriCure Announces First Use of the AtriClip PRO-Mini® Device

AtriCure to Announce First Quarter 2025 Financial Results

Apr 8, 2025, 8:00 AM EDT - 9 months ago

AtriCure to Announce First Quarter 2025 Financial Results

AtriCure to Host Analyst & Investor Day on March 26, 2025

Mar 12, 2025, 8:00 AM EDT - 10 months ago

AtriCure to Host Analyst & Investor Day on March 26, 2025

AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript

Feb 12, 2025, 10:46 PM EST - 11 months ago

AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

Feb 12, 2025, 4:01 PM EST - 11 months ago

AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results

AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results

Jan 22, 2025, 8:00 AM EST - 1 year ago

AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

Jan 13, 2025, 8:00 AM EST - 1 year ago

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2024, Provides Financial Outlook for 2025, and Announces Upcoming Analyst & Investor Day

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 23, 2024, 8:00 AM EST - 1 year ago

AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 8:00 AM EST - 1 year ago

AtriCure to Participate in the Piper Sandler 36th Annual Healthcare Conference

AtriCure to Participate in the Stifel 2024 Healthcare Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

AtriCure to Participate in the Stifel 2024 Healthcare Conference

AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript

Oct 29, 2024, 11:53 PM EDT - 1 year ago

AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript

AtriCure Reports Third Quarter 2024 Financial Results

Oct 29, 2024, 4:01 PM EDT - 1 year ago

AtriCure Reports Third Quarter 2024 Financial Results

AtriCure to Participate in the UBS Global Healthcare Conference

Oct 28, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Participate in the UBS Global Healthcare Conference

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

Oct 15, 2024, 8:00 AM EDT - 1 year ago

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

AtriCure to Announce Third Quarter 2024 Financial Results

Oct 8, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Announce Third Quarter 2024 Financial Results

AtriCure Receives CE-Mark for the EnCompass® Clamp

Oct 1, 2024, 8:00 AM EDT - 1 year ago

AtriCure Receives CE-Mark for the EnCompass® Clamp

AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device

Aug 27, 2024, 8:00 AM EDT - 1 year ago

AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device

Sparrow Mortgage Partners with Calque to Introduce The Trade-In Mortgage

Aug 22, 2024, 1:00 PM EDT - 1 year ago

Sparrow Mortgage Partners with Calque to Introduce The Trade-In Mortgage

AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation

Aug 22, 2024, 8:00 AM EDT - 1 year ago

AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation

AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 12:01 AM EDT - 1 year ago

AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript

AtriCure Reports Second Quarter 2024 Financial Results

Jul 30, 2024, 4:01 PM EDT - 1 year ago

AtriCure Reports Second Quarter 2024 Financial Results

AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference

Jul 29, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

Jul 25, 2024, 8:51 AM EDT - 1 year ago

AtriCure's Latest Projects And European Market Entry, Advancing Cardiac Care

AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China

Jul 23, 2024, 8:00 AM EDT - 1 year ago

AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China

AtriCure to Announce Second Quarter 2024 Financial Results

Jul 9, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Announce Second Quarter 2024 Financial Results

AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

May 15, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference

AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript

May 2, 2024, 1:48 AM EDT - 1 year ago

AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript

AtriCure Reports First Quarter 2024 Financial Results

May 1, 2024, 4:01 PM EDT - 1 year ago

AtriCure Reports First Quarter 2024 Financial Results

AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference

Apr 30, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Participate in the 2024 Bank of America Securities Healthcare Conference

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

Apr 18, 2024, 8:00 AM EDT - 1 year ago

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

AtriCure to Announce First Quarter 2024 Financial Results

Apr 10, 2024, 8:00 AM EDT - 1 year ago

AtriCure to Announce First Quarter 2024 Financial Results

JarvisFlow
JarvisFlow Dec. 16 at 3:36 PM
JP Morgan updates rating for AtriCure ( $ATRC ) to Overweight, target set at 42 → 48.
0 · Reply
10xStacks
10xStacks Dec. 12 at 5:46 PM
$ATRC go
1 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 4:21 PM
$ATRC unveils breakthrough dual-energy platform in surgical ablation! 🚀 📈 First patients successfully treated, advancing ATRC's platform toward a planned clinical trial next year. 🩺 Year-to-date shares up 35.5%, outshining industry’s 1.1% growth. 🔍 Zacks Rank #2 (Buy) signals bullish momentum. See what this means for ATRC's future growth 👉 https://www.zacks.com/stock/news/2803792/atrc-treats-first-patients-using-novel-dual-energy-pfa-rfa-platform?cid=sm-stocktwits-2-2803792-body-24653&ADID=SYND_STOCKTWITS_TWEET_2_2803792_BODY_24653
0 · Reply
ZacksResearch
ZacksResearch Dec. 12 at 3:21 PM
Big milestone alert for $ATRC 🚀 ATRC just treated its first patients with its dual-energy PFA-RFA platform — a meaningful step as it moves toward a clinical trial next year. That’s the kind of early traction investors watch closely. Full details here 👉 https://www.zacks.com/stock/news/2803792/atrc-treats-first-patients-using-novel-dual-energy-pfa-rfa-platform?cid=sm-stocktwits-2-2803792-teaser-24638&ADID=SYND_STOCKTWITS_TWEET_2_2803792_TEASER_24638
0 · Reply
Arcides
Arcides Nov. 30 at 5:35 PM
$ATRC chart is a mess, too much volatility, was this a shakeout?
0 · Reply
RunnerSignals
RunnerSignals Nov. 20 at 8:46 PM
mini-pulse pop! $AMZN $APTV $AR $ATRC $CYBR all waking up some bouncing some breaking and some just teasing. charts heating up… https://stocksrunner.com/news/2025-11-20-daily-market-pulse-advanced-technical-analysis
0 · Reply
maq34
maq34 Nov. 7 at 3:56 PM
$ATRC Raised 2025 Financial Outlook: Building on the strong results, AtriCure raised its full-year 2025 revenue projection to a range of $532 million to $534 million, and its adjusted EBITDA forecast to between $55 million and $57 million. PT of $54 and up…! $AMGN $ABBV $VRTX $GILD
0 · Reply
maq34
maq34 Nov. 7 at 3:53 PM
$ATRC $GILD $AMGN $ABBV $VRTX
0 · Reply
maq34
maq34 Nov. 7 at 3:43 PM
$ATRC Attractive price with solid product offering $ABBV $ASTRAZEN.NSE
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 8:27 PM
$ATRC Share Price: $31.75 Contract Selected: Apr 17, 2026 $30 Calls Buy Zone: $3.31 – $4.09 Target Zone: $6.32 – $7.72 Potential Upside: 80% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
NJgolfer
NJgolfer Oct. 16 at 9:46 PM
$ATRC Underfollowed but showing buying signs with earnings a few weeks out. The current 9 week consolidation looks like a flat base as it has only corrected a total of 12.5% from H to L. Upside targets $43 and $44
0 · Reply
Doozio
Doozio Sep. 22 at 10:46 PM
$ATRC let da 🧠 spread during 🐒🍌🧠⏰♾️
0 · Reply
SilverEagle
SilverEagle Sep. 22 at 5:06 PM
$ATRC trying to bust through 3 months highs 👀
0 · Reply
SilverEagle
SilverEagle Sep. 9 at 9:55 PM
$ATRC monthly MAs starting to curl.
0 · Reply
Doozio
Doozio Sep. 8 at 3:00 PM
$ATRC during 🐒🍌🧠⏰♾️
0 · Reply
SignalMind
SignalMind Aug. 23 at 6:19 AM
$ATRC AtriCure Inc is a medical device company focused on atrial fibrillation with steady growth trajectory
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 1:48 PM
$ATRC 😉
0 · Reply
Winning_calls
Winning_calls Aug. 4 at 3:25 AM
$ATRC pick me up @ $34
0 · Reply
JarvisFlow
JarvisFlow Jul. 30 at 11:00 AM
Needham has adjusted their stance on AtriCure ( $ATRC ), setting the rating to Buy with a target price of 44 → 45.
0 · Reply
Estimize
Estimize Jul. 30 at 10:00 AM
$ATRC reported -0.02 EPS and 136.14 revenue for Q2. http://www.estimize.com/intro/atrc?chart=historical&metric_name=eps&utm_content=ATRC&ut
0 · Reply
DonCorleone77
DonCorleone77 Jul. 29 at 8:05 PM
$ATRC AtriCure reports Q2 adjusted EPS (2c), consensus (16c) -- Q2 revenue $136.1M, consensus $130.26M. -- Cuts FY25 EPS view to (39c)-(34c) from (55c)-(50c), consensus (51c) -- Raises FY25 revenue view to $527M-$533M from $517M-$527M, consensus $523.01M.
0 · Reply
Estimize
Estimize Jul. 29 at 3:00 PM
$ATRC reports after the close, Estimize Consensus +0.01 EPS and +0.60M Revs compared to WS http://www.estimize.com/atrc/fq2-2025?utm_conten
0 · Reply